DERMALA, A Consumer Dermatology Company, Announces Issuance of the 4th U.S. Patent Covering Human Microbiome to Treat and Prevent Eczema

SAN DIEGO, June 21, 2022 /PRNewswire/ — DERMALA Inc., a science-based consumer dermatology company developing novel, microbiome-based solutions for chronic skin conditions, announced today the issuance of the U.S. Patent No. 11,364,214 – COMPOSITIONS AND METHODS FOR TREATING ECZEMA. This…

Click here to view original post